Tag Archives: Alexander Kulla

Merck’s MAVENCLAD Shows Sustained Reduction in Neuronal Injury for Multiple Sclerosis Patients

(IN BRIEF) Merck, a prominent science and technology company, has revealed new findings from the MAVENCLAD® (cladribine tablets) MAGNIFY-MS study at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan. The study demonstrated that patients with relapsing multiple sclerosis (RMS) experienced a … Read the full press release